Regulatory Focus™ > News Articles > 4 > Recon: Veritas to Acquire GE Unit for $1B; Celgene COO Resigns

Recon: Veritas to Acquire GE Unit for $1B; Celgene COO Resigns

Posted 03 April 2018 | By Ana Mulero 

Recon: Veritas to Acquire GE Unit for $1B; Celgene COO Resigns

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US In Focus: International Pharmaceuticals & Biotechnology
  • After 2016's monster bonus—and investor complaints—Valeant CEO's pay crashes from $62M to $5M (Fierce)
  • Pharma vet Stan Bukofzer joins Depomed as CMO/CSO (Fierce)
  • Allergan Weighs Options for Women's Health Unit (Bloomberg)
  • Pharma's cheap stocks spell investment opportunity for traders: JP Morgan (CNBC-$)
  • High-flying biotech Loxo tempers bullish view for cancer drug (Reuters)
  • The top 15 drug patent expirations of 2018 (Fierce)
  • Amgen’s money-back guarantee for its pricey cholesterol drug may not deliver (STAT-$)
  • Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures (Endpoints)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Amgen, Sandoz trial over Enbrel patents likely delayed—and a biosimilar could be, too (Fierce)
  • Drug-loaded hydrogel responds to arthritis flare-ups in real time (STAT)
  • Allergan, Richter prep for FDA OK with positive PhIII for cariprazine in bipolar depression (Endpoints) (Budapest Business Journal)
  • NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials (NCI)
  • The Alzheimer’s R&D Odyssey Comes to Another Fork in the Road (Endpoints)
  • Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies (Press)
Medical Devices
  • Cardioform Septal Occluder Wins FDA Approval for PFO Closure (MedPage Today) (Press)
  • BD’s C.R. Bard must pay $4m in IVC bellwether (MassDevice)
  • Twilight of the medtech conglomerates (EP Vantage)
  • ResMed is disrupting connected health: Here’s how (Medical Design & Outsourcing)
  • At-Home DNA Test Kits Are Blowing Up In Popularity. But Are They Accurate? (Fortune)
  • Experts challenge digital health developers to show value in an often-hyped field (STAT-$)
  • ReShape unveils $6M offering, stock falls 50% (Fierce) (Press)
  • The Code: a three-part video series investigating the roots of today’s most promising genetic technologies (STAT)
  • NN Inc. to pay $375m for Paragon Medical (MassDevice) (Press)
  • DrChrono to offer Apple hardware leasing for physician practices (mobihealthnews)
  • AVITA Medical Announces Schedule for Six RECELL Device Presentations at American Burn Association (ABA) 50th Annual Meeting (Press)
  • WellDoc Announces Providence Health & Services’ Implementation of BlueStar Digital Therapeutic in a Pilot Program for Individuals with Type 2 Diabetes (Press)
US: Assorted & Government
  • New RTA Policy Has Implications for Combination Products (FDA Law Blog)
  • The Mysteries of Pass-Through Status: Why Medicare and Seniors Are Now Paying More for Lower-Cost Biosimilars at Hospitals (Drug Channels)
  • Wisconsin and West Virginia Pass Biosimilar Legislation - Big Molecule Watch (Goodwin)
  • Supreme Court rejects appeal to release anti-abortion activists' videos (Reuters)
  • White House is urged to sidestep patents on opioid overdose treatment (STAT-$)
  • Why Trump's Health Department Quietly Scrubbed Important Breast Cancer Info from Its Website (Fortune)
  • HHS seeks another delay for 340B changes (Modern Healthcare)
  • Teva, Valeant price-hike plans trigger warnings under California's new transparency law: report (Fierce)
  • Diabetes Clinic Founder Arrested on Bribery Charges (MedPage Today)
  • Washington insider's 'secret sauce' fueled NY hedge fund, U.S. says at trial (Reuters)
  • State Department puts out RFI for a new EHR (Healthcare IT News)
  • What They Said – FDA Press Releases 1st Quarter 2018 (Eye on FDA)
  • HHS Solicitation of Nominations for Membership on the National Vaccine Advisory Committee (HHS)
  • First-quarter acquisition activity hints at a big year (EP Vantage)
Upcoming Meetings & Events Europe
  • Brexit Agreement: Reset your clocks! (Emergo Group)
  • Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation (EURACTIV)
  • NHS to fund balloon pulmonary angioplasty in the UK (PharmaTimes) (NHS)
  • NHS England publishes guidelines curbing OTC prescriptions (PharmaTimes)
  • France puts healthcare at heart of $1.8B AI strategy (Fierce)
  • Servier and Scandicure to conduct research in metabolic diseases (The Pharma Letter-$)
  • Russia’s Gem-Standard to build one of country’s largest plants for blood plasma drugs (The Pharma Letter-$)
  • EC follows US example in granting new Xgeva indication (The Pharma Letter-$) (Press)
  • CorWave wins $4m from French Innovation Challenge (MassDevice)
  • Brainomix raises $10m for AI stroke imaging tech (MassDevice)
  • Reva inks distro deal for bioresorbable scaffolds in Turkey (Drug Delivery Business News)
  • Redx Pharma updates clinical trial of porcupine inhibitor, RXC004 (pharmabiz)
  • Swissmedic has a new Executive Director – new leadership team complete (Swissmedic)
  • Rhythm Pharma in-licenses PWS candidate from Takeda (BioSpectrum)
  • Tuberculosis services in Moscow extend “health for all” even to the most vulnerable (WHO)
  • Algatech Invests in Supreme Health (Press)
  • Medtronic Brings Value-based Healthcare to Taiwan (Taiwan Business Topics)
  • Keytruda Filed for Tumor-Agnostic Indication in Japan (PharmaJapan)
  • Doctors in India at breaking point, courtesy continuing attacks: Lancet report (Hindustan Times)
  • 'Pharma may see recovery with FY19 profit set to jump 20-22%' (Times of India)
  • Medical device firms to go against ‘discriminatory’ public procurement norms as response deadline nears (pharmabiz)
  • NPPA fixes retail prices of 869 formulations under DPCO, 2013 as per April 2, 2018 order (pharmabiz)
  • Half yearly performance snapshot: July to December 2017 (TGA)
  • Political battle over private health insurance rebate heats up (The Sydney Morning Herald)
  • Police use Apple Watch health data as evidence in murder case (Mashable)
  • Big pharma under fire for spruiking strong painkillers to doctors (The Sydney Morning Herald)
  • What should and shouldn’t be covered by medicare? (The Globe and Mail)
  • Canadians want options to a failing health-care system (Toronto Sun)
  • Doctors say government neglect, mismanagement to blame for sorry state of health care (CBC News)
  • Update on the Proposed Regulation of Cannabis: Health Canada Releases Summary of Public Feedback  (Lexology)
General Health & Other Interesting Articles
  • Can Doctors Choose Between Saving Lives and Saving a Fortune? (NYT Magazine)
  • What It’s Like Living Without Health Insurance in America (Bloomberg)
  • Many doctors don’t pay attention to home health care plans (Reuters)
  • Aging Populations Will Challenge Healthcare Systems All Over The World (Forbes)
  • Expensive prescriptions have patients skipping their meds. What can doctors do about it? (STAT)
  • Commentary: Why We Need to Give Doctors Time to Listen (Fortune)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.